Business
Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in three virtual investor conferences during the week of January 11, 2021.\n\nH.C. Wainwright BioConnect Conference:\n\nThe Company will be participating in the H.C. Wainwright BioConnect Conference with a virtual presentation that will be available on demand beginning at 6:00 am EST on January 11, 2021 and can be viewed here.\n\nThe virtual presentation will also be available on the Company’s website here.\n\nBiotech Showcase 2021 Digital:\n\nThe Company will be participating in the Biotech Showcase partnering event with an on-demand presentation available to conference participants.\n\nBIO Partnering at JPM: \n\nThe Company will be participating in the BIO partnering event at the 2021 JP Morgan Healthcare Conference.\n\nAbout Breast Cancer and HER2/neu Positivity\n\nOne in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.\n\nAbout Greenwich LifeSciences, Inc.\n\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse...